Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.95−0.10 (-9.87%)
Close on Nov 16, 2026Market cap $26.27MP/E –Yield –
Inmune Bio enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Inmune Bio's enterprise value was $12.01M on Nov 11, 2026, against $18.52M a year earlier. Over the last 5 years it ranged from $5.29M to $194.21M, with a median of $82.92M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $12.01M | -12.6% |
| 2025 | Dec 31, 2025 | $13.74M | -81.0% |
| 2024 | Dec 31, 2024 | $72.49M | -54.9% |
| 2023 | Dec 29, 2023 | $160.69M | +182.0% |
| 2022 | Dec 30, 2022 | $56.98M | -41.6% |
| 2021 | Dec 31, 2021 | $97.53M | -52.9% |
| 2020 | Dec 31, 2020 | $207.26M | +276.6% |
| 2019 | Dec 31, 2019 | $55.04M | – |
See a number that looks wrong?